90281 |Immune globulin (Ig), human, for intramuscular use||IG|86 ||2020/04/14|169 90283 |Immune globulin (IgIV), human, for intravenous use||IGIV|87 ||2020/04/14|170 90287 |Botulinum antitoxin, equine, any route||botulinum antitoxin|27 ||2017/02/28|171 90291 |Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use||CMVIG|29 ||2020/04/14|172 90296 |Diphtheria antitoxin, equine, any route||diphtheria antitoxin|12 ||2017/02/28|173 90371 |Hepatitis B immune globulin (HBIg), human, for intramuscular use||HBIG|30 ||2020/04/14|174 90375 |Rabies immune globulin (RIg), human, for intramuscular and/or subcutaneous use||RIG|34 ||2020/04/14|175 90376 |Rabies immune globulin, heat-treated (RIg-HT), human, for intramuscular and/or subcutaneous use||RIG|34 ||2020/04/14|176 90378 |Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each||RSV-MAb|93 ||2020/04/14|177 90379 |Respiratory syncytial virus immune globulin (RSV-IgIV), human, for intravenous use||RSV-IGIV|71 ||2017/02/28|178 90389 |Tetanus immune globulin (TIg), human, for intramuscular use||TIG|13 ||2020/04/14|179 90393 |Vaccinia immune globulin, human, for intramuscular use||vaccinia immune globulin|79 ||2020/04/14|180 90396 |Varicella-zoster immune globulin, human, for intramuscular use||VZIG|36 ||2020/04/14|150 90470 |H1N1 immunization administration (intramuscular, intranasal), including counseling when performed||Novel Influenza-H1N1-09, all formulations|128 ||2017/02/28|297 90476 |Adenovirus vaccine, type 4, live, for oral use||adenovirus, type 4|54 ||2020/04/14|151 90477 |Adenovirus vaccine, type 7, live, for oral use||adenovirus, type 7|55 ||2020/04/14|152 90581 |Anthrax vaccine, for subcutaneous or intramuscular use||anthrax|24 ||2020/04/14|153 90585 |Bacillus Calmette-Guerin vaccine (BCG) for tuberculosis, live, for percutaneous use||BCG|19 ||2020/04/14|154 90611 |Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use||Vaccinia, smallpox monkeypox vaccine live, PF, SQ or ID injection|206 |CPT Code to be used for JYNNEOS vaccine|2022/07/27|356 90619 |Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use||meningococcal polysaccharide (groups A, C, Y, W-135) TT conjugate|203 ||2020/07/28|337 90620 |Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use||meningococcal B, OMV|163 ||2020/04/14|314 90621 |Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use||meningococcal B, recombinant|162 ||2020/04/14|313 90622 |Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for percutaneous use||vaccinia (smallpox)|75 |CPT Code to be used for ACAM2000 vaccine|2022/07/27|357 90625 |Cholera vaccine, live, adult dosage, 1 dose schedule, for oral use||cholera, live attenuated|174 ||2020/04/14|327 90626 |Tick-borne encephalitis virus vaccine, inactivated; 0.25 mL dosage, for intramuscular use||Tick-borne encephalitis, inactivated, PF, 0.25mL|223 ||2021/09/13|343 90627 |Tick-borne encephalitis virus vaccine, inactivated; 0.5 mL dosage, for intramuscular use||Tick-borne encephalitis, inactivated, PF, 0.5mL|224 ||2021/09/13|344 90630 |Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use||influenza, intradermal, quadrivalent, preservative free|166 ||2020/04/14|316 90632 |Hepatitis A vaccine (HepA), adult dosage, for intramuscular use||Hep A, adult|52 ||2020/04/14|155 90633 |Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use||Hep A, ped/adol, 2 dose|83 ||2020/04/14|156 90634 |Hepatitis A vaccine (HepA), pediatric/adolescent dosage-3 dose schedule, for intramuscular use||Hep A, ped/adol, 3 dose|84 ||2020/04/14|157 90636 |Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use||Hep A-Hep B|104 ||2020/04/14|158 90644 |Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae type b vaccine (Hib-MenCY), 4 dose schedule, when administered to children 6 weeks-18 months of age, for intramuscular use||Meningococcal C/Y-HIB PRP|148 ||2020/04/14|317 90645 |Hemophilus influenza b vaccine (Hib), HbOC conjugate (4 dose schedule), for intramuscular use||Hib (HbOC)|47 ||2017/02/28|159 90646 |Hemophilus influenza b vaccine (Hib), PRP-D conjugate, for booster use only, intramuscular use||Hib (PRP-D)|46 ||2017/02/28|160 90647 |Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use||Hib (PRP-OMP)|49 ||2020/04/14|161 90648 |Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use||Hib (PRP-T)|48 ||2020/04/14|162 90649 |Human Papillomavirus vaccine, types 6, 11, 16, 18, quadrivalent (4vHPV), 3 dose schedule, for intramuscular use||HPV, quadrivalent|62 ||2020/04/14|163 90650 |Human Papillomavirus vaccine, types 16, 18, bivalent (2vHPV), 3 dose schedule, for intramuscular use||HPV, bivalent|118 ||2020/04/14|164 90651 |Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use||HPV9|165 ||2020/04/14|318 90653 |Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use||influenza, trivalent, adjuvanted|168 ||2020/04/14|325 90654 |Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use||influenza, seasonal, intradermal, preservative free|144 ||2020/04/14|302 90655 |Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use||Influenza, seasonal, injectable, preservative free|140 ||2020/04/14|165 90656 |Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use||Influenza, seasonal, injectable, preservative free|140 ||2020/04/14|166 90657 |Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use||Influenza, seasonal, injectable|141 ||2020/04/14|167 90658 |Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use||Influenza, seasonal, injectable|141 ||2020/04/14|168 90659 |Influenza virus vaccine, whole virus, for intramuscular or jet injection use||influenza, whole|16 ||2017/02/28|181 90660 |Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use||influenza, live, intranasal|111 ||2020/04/14|182 90661 |Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use||Influenza, injectable, MDCK, preservative free|153 ||2020/04/14|310 90662 |Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use||Influenza, high dose seasonal|135 ||2020/04/14|292 90662 |Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use||influenza, high-dose, quadrivalent|197 ||2020/04/14|292 90663 |Influenza virus vaccine, pandemic formulation, H1N1||Novel Influenza-H1N1-09, all formulations|128 ||2017/02/28|293 90664 |Influenza virus vaccine, live (LAIV), pandemic formulation, for intranasal use||Novel Influenza-H1N1-09, nasal|125 ||2020/04/14|294 90665 |Lyme disease vaccine, adult dosage, for intramuscular use||Lyme disease|66 ||2017/02/28|183 90666 |Influenza virus vaccine (IIV), pandemic formulation, split virus, preservative free, for intramuscular use||Novel influenza-H1N1-09, preservative-free|126 ||2020/04/14|300 90668 |Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use||Novel influenza-H1N1-09|127 ||2020/04/14|296 90669 |Pneumococcal conjugate vaccine, 7 valent, for intramuscular use||pneumococcal conjugate PCV 7|100 ||2017/02/28|184 90670 |Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use||Pneumococcal conjugate PCV 13|133 ||2020/04/14|185 90671 |Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use||Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF|215 ||2021/09/13|345 90672 |Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use||influenza, live, intranasal, quadrivalent|149 ||2020/04/14|319 90673 |Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use||influenza, recombinant, injectable, preservative free|155 ||2020/04/14|311 90674 |Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use||Influenza, injectable, MDCK, preservative free, quadrivalent|171 ||2020/04/14|326 90675 |Rabies vaccine, for intramuscular use||rabies, unspecified formulation|90 ||2020/04/14|186 90676 |Rabies vaccine, for intradermal use||rabies, intradermal injection|40 ||2020/04/14|187 90677 |Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use||Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF|216 ||2021/09/13|346 90680 |Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use||rotavirus, pentavalent|116 ||2020/04/14|188 90681 |Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use||rotavirus, monovalent|119 ||2020/04/14|189 90682 |Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use||influenza, recombinant, quadrivalent,injectable, preservative free|185 ||2020/04/14|332 90685 |Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use||Influenza, injectable,quadrivalent, preservative free, pediatric|161 ||2020/04/14|305 90686 |Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use||influenza, injectable, quadrivalent, preservative free|150 ||2020/04/14|306 90687 |Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use||influenza, injectable, quadrivalent|158 ||2020/04/14|312 90688 |Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use||influenza, injectable, quadrivalent|158 ||2020/04/14|308 90690 |Typhoid vaccine, live, oral||typhoid, oral|25 ||2020/04/14|190 90691 |Typhoid vaccine, Vi capsular polysaccharide (ViCPs), for intramuscular use||typhoid, ViCPs|101 ||2020/04/14|191 90692 |Typhoid vaccine, heat- and phenol-inactivated (H-P), for subcutaneous or intradermal use||typhoid, parenteral|41 ||2017/02/28|192 90693 |Typhoid vaccine, acetone-killed, dried (AKD), for subcutaneous use (U.S. military)||typhoid, parenteral, AKD (U.S. military)|53 ||2017/02/28|193 90694 |Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use||Influenza vaccine, quadrivalent, adjuvanted|205 ||2020/04/14|336 90696 |Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use||DTaP-IPV|130 ||2020/04/14|194 90697 |Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use||DTaP,IPV,Hib,HepB|146 ||2020/04/14|328 90698 |Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use||DTaP-Hib-IPV|120 ||2020/04/14|195 90700 |Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use||DTaP|20 ||2020/04/14|196 90701 |Diphtheria, tetanus toxoids, and whole cell pertussis vaccine (DTP), for intramuscular use||DTP|01 ||2017/02/28|197 90702 |Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use||DT (pediatric)|28 ||2020/04/14|198 90703 |Tetanus toxoid adsorbed, for intramuscular use||tetanus toxoid, adsorbed|35 ||2017/02/28|199 90704 |Mumps virus vaccine, live, for subcutaneous use||mumps|07 ||2017/02/28|200 90705 |Measles virus vaccine, live, for subcutaneous use||measles|05 ||2017/02/28|201 90706 |Rubella virus vaccine, live, for subcutaneous use||rubella|06 ||2017/02/28|202 90707 |Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use||MMR|03 ||2020/04/14|203 90708 |Measles and rubella virus vaccine, live, for subcutaneous use||M/R|04 ||2017/02/28|204 90710 |Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use||MMRV|94 ||2020/04/14|205 90712 |Poliovirus vaccine, (any type[s]) (OPV), live, for oral use||OPV, Unspecified|182 ||2017/02/28|206 90713 |Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use||IPV|10 ||2020/04/14|207 90714 |Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use||Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed|09 |Beginning in 2005, this CPT code maps to TD preservative free. Remapped to CVX code 09 10/2021 to support active products mapped to that code.|2021/10/08|208 90715 |Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use||Tdap|115 ||2020/04/14|210 90716 |Varicella virus vaccine (VAR), live, for subcutaneous use||varicella|21 ||2020/04/14|211 90717 |Yellow fever vaccine, live, for subcutaneous use||Yellow fever, unspecified formulation|184 ||2020/04/14|212 90720 |Diphtheria, tetanus toxoids, and whole cell pertussis vaccine and Hemophilus influenza B vaccine (DTP-Hib), for intramuscular use||DTP-Hib|22 ||2017/02/28|214 90721 |Diphtheria, tetanus toxoids, and acellular pertussis vaccine and Hemophilus influenza B vaccine (DTaP/Hib), for intramuscular use||DTaP-Hib|50 ||2017/02/28|215 90723 |Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use||DTaP-Hep B-IPV|110 ||2020/04/14|216 90724 |Influenza virus vaccine||influenza, unspecified formulation|88 ||2017/03/03|217 90725 |Cholera vaccine for injectable use||cholera, unspecified formulation|26 ||2017/02/28|218 90726 |Rabies vaccine||rabies, unspecified formulation|90 ||2017/03/03|219 90727 |Plague vaccine, for intramuscular use||plague|23 ||2017/02/28|220 90728 |BCG vaccine||BCG|19 ||2017/03/03|221 90730 |Hepatitis A vaccine||Hep A, unspecified formulation|85 ||2017/03/03|222 90731 |Hepatitis B vaccine||Hep B, unspecified formulation|45 ||2017/03/03|223 90732 |Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use||pneumococcal polysaccharide PPV23|33 ||2020/04/14|224 90733 |Meningococcal polysaccharide vaccine, serogroups A, C, Y, W-135, quadrivalent (MPSV4), for subcutaneous use||meningococcal MPSV4|32 ||2020/04/14|225 90734 |Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use||meningococcal MCV4P|114 ||2020/04/14|226 90735 |Japanese encephalitis virus vaccine, for subcutaneous use||Japanese encephalitis SC|39 ||2017/02/28|227 90736 |Zoster (shingles) vaccine (HZV), live, for subcutaneous injection||zoster live|121 ||2020/04/14|228 90737 |Hemophilus influenza B||Hib, unspecified formulation|17 ||2017/03/03|229 90738 |Japanese encephalitis virus vaccine, inactivated, for intramuscular use||Japanese Encephalitis IM|134 ||2020/04/14|230 90739 |Hepatitis B vaccine (HepB), adult dosage, 2 dose schedule, for intramuscular use||HepB-CpG|189 ||2020/04/14|324 90740 |Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use||Hep B, dialysis|44 ||2020/04/14|231 90741 |Immunization, passive; immune serum globulin, human (ISG)||IG, unspecified formulation|14 ||2017/03/03|232 90743 |Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use||Hep B, adult|43 ||2020/04/14|233 90744 |Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use||Hep B, adolescent or pediatric|08 ||2020/04/14|234 90745 |Hepatitis B vaccine, adolescent/high risk infant dosage, for intramuscular use||Hep B, adolescent/high risk infant|42 ||2017/03/03|235 90746 |Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use||Hep B, adult|43 ||2020/04/14|236 90747 |Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use||Hep B, dialysis|44 |Note that the NDCs for Engerix-B are mapped to CVX 43 which is not specific to dialysis use|2020/04/14|237 90748 |Hepatitis B and Haemophilus influenzae type b vaccine (Hib-HepB), for intramuscular use||Hib-Hep B|51 ||2020/04/14|238 90750 |Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use||zoster recombinant|187 ||2018/06/25|334 90756 |Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use||Influenza, injectable, MDCK, quadrivalent, preservative|186 |Effective 1/1/2018|2020/04/14|333 90758 |Zaire ebolavirus vaccine, live, for intramuscular use||Ebola Zaire vaccine, live, recombinant, 1mL dose|204 ||2021/09/13|347 90759 |Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use||HepB recombinant, 3-antigen, Al(OH)3|220 ||2021/09/13|348 91300 |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use||COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose|208 |COVID-19 Vaccine - EUA authorized 12/11/2020|2022/09/02|338 91301 |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use||COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose|207 |COVID-19 Vaccine - BLA Licensed and EUA authorized|2022/09/02|339 91302 |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use||COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL |210 |COVID-19 Vaccine - EUA submission withdrawn |2022/09/02|340 91303 |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use||COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL|212 |COVID-19 Vaccine - EUA authorized 2/27/2021|2022/09/02|341 91304 |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use||COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL|211 |COVID-19 Vaccine - EUA authorized for ages 12+ yrs |2022/09/02|342 91305 |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use||COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose|217 |COVID-19 Vaccine - EUA authorized for primary series and IC, EUA rescinded 8/31/202 for monovalent boosters |2022/09/02|349 91306 |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use||COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose|207 |COVID-19 Vaccine - EUA authorization rescinded 8/31/2022 for adult monovalent booster dose|2022/09/02|350 91307 |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use||COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose|218 |COVID-19 Vaccine - EUA authorized, pediatric 5 yrs through 11 yrs dose requires dilution|2022/09/02|351 91308 |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use||COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose|219 |COVID-19 Vaccine - EUA authorized for children under 5 yrs|2022/09/02|352 91309 |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use||COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose|221 |COVID-19 Vaccine - EUA authorized for pediatric, EUA rescinded 8/31/2022 for adult monovalent booster dose|2022/09/02|353 91310 |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use||COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL|225 |COVID-19 Vaccine - Potential EUA authorization booster dose|2022/08/30|355 91311 |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use||COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose|228 |COVID-19 Vaccine - EUA authorized for ages 6 mo through 5 yrs|2022/09/02|354 91312 |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use||COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose|300 |COVID-19 Vaccine - EUA authorized 8/31/2022 bivalent booster ages 12+ yrs|2022/09/02|361 91313 |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use||COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose|229 |COVID-19 Vaccine - EUA authorized 8/31/2022 bivalent booster for ages 18+ yrs, potential EUA ages 6 yrs through 17 yrs|2022/09/02|360 91314 |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use||COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose|229 |COVID-19 Vaccine - Potential EUA authorization bivalent booster for ages 6 yrs through 11 yrs|2022/09/02|359 91315 |Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use||COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL dose|301 |COVID-19 Vaccine - Potential EUA authorization bivalent booster for ages 5 yrs through 11 yrs|2022/09/02|358